Immunoprecise Antibodies Ltd
XTSX:IPA
Immunoprecise Antibodies Ltd
Total Liabilities & Equity
Immunoprecise Antibodies Ltd
Total Liabilities & Equity Peer Comparison
Competitive Total Liabilities & Equity Analysis
Latest Figures & CAGR of Competitors
Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Immunoprecise Antibodies Ltd
XTSX:IPA
|
Total Liabilities & Equity
CA$67m
|
CAGR 3-Years
40%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
Total Liabilities & Equity
$1.5B
|
CAGR 3-Years
14%
|
CAGR 5-Years
133%
|
CAGR 10-Years
N/A
|
|
Arch Biopartners Inc
XTSX:ARCH
|
Total Liabilities & Equity
CA$636.5k
|
CAGR 3-Years
-5%
|
CAGR 5-Years
11%
|
CAGR 10-Years
32%
|
|
Replicel Life Sciences Inc
XTSX:RP
|
Total Liabilities & Equity
CA$331.5k
|
CAGR 3-Years
-5%
|
CAGR 5-Years
23%
|
CAGR 10-Years
-20%
|
|
Innovotech Inc
XTSX:IOT
|
Total Liabilities & Equity
CA$1.1m
|
CAGR 3-Years
5%
|
CAGR 5-Years
33%
|
CAGR 10-Years
12%
|
See Also
What is Immunoprecise Antibodies Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
67m
CAD
Based on the financial report for Apr 30, 2021, Immunoprecise Antibodies Ltd's Total Liabilities & Equity amounts to 67m CAD.
What is Immunoprecise Antibodies Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 3Y
40%
Over the last year, the Total Liabilities & Equity growth was 146%. The average annual Total Liabilities & Equity growth rates for Immunoprecise Antibodies Ltd have been 40% over the past three years .